Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5768
The Orapred product line is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer. Orapred ODT utilizes a proprietary orally disintegrating tablet technology to provide a taste-masked, non-refrigerated and convenient formulation of prednisolone. Licensor retains rights outside North America.
New Drug Applications
Abbreviated New Drug Applications
Orapred (Prednisolone Sodium Phosphate Oral Solution), 20.2 mg/ 5 ML, (equivalent to 15 mg (base)/ 5 ML) – ANDA 75-117
Orapred RT (Prednisolone Sodium Phosphate Oral Solution), 20.2 mg/ 5 ML, (equivalent to 15 mg (base)/ 5 ML) – ANDA 77-485
505(B)(2) New Drug Application
Orapred ODT (Prednisolone Sodium Phosphate
Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg Prednisolone base) – NDA 21-959
Development Licensed Patents
US 5178878 A
CIMA LABS INC.
CIMA, CIMA LABS INC. OraSolvÂ®, PakSolvÂ®, DuraSolvÂ®, and are Cima Trademarks.
Taste Masking Related Licensed Patents
Pleasant Tasting Aqueous Liquid Composition of a Bitter-Tasting Drug
Anaebonam, Aloysius O.
Fawzy, Abdel A.
Room Temperature Stable Aqueous Liquid Pharmaceutical Composition
Emmett Clemente, Bhiku Patel, Kuljit Bhatia, Frank L. Sorgi, and Emil D. Kakkis
Medicis Pharmaceutical Corporation, Ascent Pediatrics Inc., BioMarin Pharmaceutical Inc.
Transferred Inventory of Orapred
8 oz. Trade bottles
8 oz. Samples
6 pack, 20 ml samples
8 oz. Authorized generic bottles
IPSCIO Record ID: 6891
The Licensor receives royalty revenues on Orapred products, a product acquired in 2004 and subLicensed in 2006.
IPSCIO Record ID: 248396
Licensor grants to Licensee and its permitted sublicensees and Affiliates a non-exclusive license to the Licensor Trademarks identified during the term of this Agreement for the purpose of performing its obligations under this Agreement. The Trademarks are to be used in labeling of Licensed Product as requested as well as use name and derivations thereof in promoting, marketing and selling of Licensed Product in the Territory.
Oral Disintegrating Tablets shall mean a solid tablet dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds when taken orally.
Trademarks shall mean the trademarks, tradenames (and registrations and applications therefor) controlled by each of the parties and used on Licensed Product, (Oral Disintegrating Tablets) including, initially the applicable Licensor Trademarks listed hereto and the applicable Ascent Trademarks listed hereto.
CIMA LABS INC.
Licensor Technical Information shall mean (a) techniques and data, including ideas, inventions (including patentable inventions, but excluding inventions covered by Licensor Licensed Patents), practices methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing, patent data or descriptions relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates and (b) chemical formulations, compositions of matter, product samples and assays relating to Licensed Product, including, but not limited to, those that relate to DuraSolv(R)Technology, PakSolv(R)Technology and/or OraSolv(R)Technology, owned or Controlled by Licensor and/or its Affiliates. Licensor Technical Information shall include Developed Intellectual Property. Licensor Technical Information shall not include any Work Product.
Licensor Licensed Patents shall mean the patents and patent applications owned or Controlled by Licensor and/or its Affiliates that claim Licensed Product, the DuraSolv(R) Technology, the PakSolv(R) Technology and/or the OraSolv(R) Technology as related to Licensed Product, and its manufacture, its packaging, or its use, its import or its sale and including any extension, reissue, renewal, reexamination or continuation-in-part of such patents or patent applications. Licensor Licensed Patents shall include Developed Intellectual Property. Licensor Licensed Patents shall not include any Work Product. The initial list of Licensor Licensed Patents is set forth.
U.S. Pat. No. 5,178,878 – Effervescent dosage form with microparticles
U.S. Pat. No. 6,155,423 – Blister package and packaged tablet
U.S. Pat. No. 6,024,981 – Rapidly dissolving robust dosage form
U.S. Pat. No. 6,221,392 – Rapidly dissolving robust dosage form
DuraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patents 6,024,981 and 6,221,392 and PCT Published Application No. WO 98/46215.
PakSolv(R)Technology shall mean the packaging system generally described in U.S. Patents 6,155,423; 6,269,615 and 6,311,462.
OraSolv(R)Technology shall mean the fast-dissolving drug delivery system generally described in U.S. Patent 5,178,878 and U.S. Patent Application 08/468,913.
IPSCIO Record ID: 227284
Licensor grants to Licensee an exclusive, royalty bearing license to use the Licensor Trademarks to market, distribute and sell the Products, during the term of this Agreement, for all indications and for all agreed upon Product line extensions in the Territory.
LicensorTarget Completion Date
December 01, 2002
HCI 0.25 mg
March 31, 2003
#5 selegiline HCI
#6 diphenoxylate HCVatropine sulfate
2.5 mw0.025 mg
#7 dicyclomine HCI
Licensor Patents shall mean United States patent nos. 6,024,981 and 6,221,392 (Rapidly Dissolving Robust Dosage Form) and any patents and patent applications resulting therefrom, including any extension, reissue, renewal, reexamination or continuation-in-part of such patent or patent application. To the extent that the OraSolv(R) and PakSolv(TM) technology is used with respect to any Product pursuant, the term 'Licensor Patents' shall, with respect to such Product, be deemed to include United States patent nos. 5,178,878, 6,155,423, 6,269,615 and 6,311,462 and any patents and patent applications resulting therefrom, including any extension, reissue, renewal, reexamination or continuation-in-part of such patent or patent application.
Licensor Trademarks shall mean the Licensor(R), DuraSolv(R), PakSolv(TM), OraSolv(R) and Meltabs(R) trademarks.
Licensor Technology shall mean all of the Licensor Patents and all of Licensors trade secrets, technology, know-how and all other information necessary for the manufacture of the Products including, without limitation, that relate to Licensors DuraSolv(R), PakSolv(TM) and OraSolv(R) technologies.
OraSolv technology is an oral dosage form that combines taste masked drug ingredients with a fast dissolving, low-effervescence system. The OraSolv tablet dissolves quickly in the mouth without chewing or the need for water.
IPSCIO Record ID: 66659
Intellectual Property relates to orally disintegrating tablet formulations of pharmaceutical products.
Certain Licensed Patent Rights
U.S. Patent No. 6,149,938
U.S. Patent Application Serial No. 12/034,928
'Product' or 'Products' means (i) the finished pharmaceutical forms of phentermine hydrochloride orally disintegrating tablets in 15 mg, 30 mg and 37.5 mg dosages and (ii) any Improvements.
'Product NDA' means NDA # 20-2088.